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Abstract
Background: Previous studies of human and simian immunodeficiency virus (HIV and SIV) have demonstrated that
adaptive mutations selected during the course of infection alter viral replicative fitness, persistence, and
pathogenicity. What is unclear from those studies is the impact of transmission on the replication and
pathogenicity of the founding virus population. Using the SIV-macaque model, we examined whether the route of
infection would affect the establishment and replication of two SIVmne variants of distinct in vitro and in vivo
biological characteristics. For these studies, we performed dual-virus inoculations of pig-tailed macaques via
intrarectal or intravenous routes with SIVmneCl8, a miminally pathogenic virus, and SIVmne027, a highly
pathogenic variant that replicates more robustly in CD4
+ T cells.
Results: The data demonstrate that SIVmne027 is the dominant virus regardless of the route of infection,
indicating that the capacity to replicate efficiently in CD4
+ T cells is important for fitness. Interestingly, in
comparison to intravenous co-infection, intrarectal inoculation enabled greater relative replication of the less
pathogenic virus, SIVmneCl8. Moreover, a higher level of SIVmneCl8 replication during primary infection of the
intrarectally inoculated macaques was associated with lower overall plasma viral load and slower decline in CD4
+
T cells, even though SIVmne027 eventually became the dominant virus.
Conclusions: These results suggest that the capacity to replicate in CD4
+ T cells is a significant determinant of SIV
fitness and pathogenicity. Furthermore, the data also suggest that mucosal transmission may support early
replication of phenotypically diverse variants, while slowing the rate of CD4
+ T cell decline during the initial stages
of infection.
Background
Human and simian immunodeficiency virus (HIV and
SIV) undergo genetic and biological changes during the
course of infection that correlate with increased viral
load and disease progression. The evolution of the virus
population results from direct competition of viral var-
iants [1,2], intense immune pressure [3], and target cell
availability [4,5]. Thus, viral fitness is a dynamic term
and is dependent on the mutations and conditions
under which viral replication is taking place. For exam-
ple, CD8 epitope escape mutants may show increased
fitness compared to wild type virus in context of a spe-
cific restricting HLA allele, but with a corresponding
loss of replication capacity and, subsequently, lower
levels of persistent replication [6,7]. These types of
mutations may revert during transmission to an unrest-
ricted-HLA recipient, indicating that they impair fitness
in vivo [8,9]. Likewise, antiretroviral drug resistant
mutants may show higher fitness compared to wild type
virus in the presence of the inhibitor, but lower fitness
when the drug is withdrawn [10-12]. Additionally, viral
variants isolated during early and late stages of infection
may differ in their phenotypic properties and pathogeni-
city, with late-stage variants demonstrating increases in
replication capacity and virulence [13-16]. However,
questions about HIV-1 fitness and pathogenicity have
been incompletely addressed because of inadequate tis-
sue culture assays and the absence of a suitable HIV-1
animal model of infection to confirm correlative
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An alternative approach to address questions of HIV
fitness and pathogenicity has been to use the simian
immunodeficiency virus (SIV)-macaque model [17]. The
advantage of the model is that the fitness and patho-
genicity of a virus of known genotype and biological
phenotype can be defined after experimental inoculation
into multiple hosts. Studies have shown how immune
pressure, by both the humoral and cellular immune
responses of the macaque, affects replication and patho-
genicity [18-22]. However, while cytotoxic T cell (CTL)
escape mutations cause a loss of fitness, glycosylation
changes in the envelope protein that reduce immuno-
genicity and neutralizatione n h a n c er e p l i c a t i o ni nt h e
host. Other experiments have shown that enhancement
of fitness and pathogenicity may involve more than
selection due to immune pressure. SIV variants that
evolve increased virulence compared to the parental
virus have inherent gains in infectivity and replication
capacity that result from mutations selected in various
determinants within the viral genome, including, env
gp41 [23], nef [22,24-31] and gag ca [32], gag-pol [33],
and rt [34].
Earlier studies primarily focused on defining how HIV
and SIV adapt to the environment of the host in order
to persistently replicate. What is less clear from those
studies is the effect of transmission and the properties
of the infecting viruses on the replicative fitness and
pathogenicity of the founding virus population, which is
commonly different from variants present at later stages
of infection and disease [17,35-37]. In the present study,
we used the SIV-macaque model to examine whether
the route of infection would affect the establishment
and replication of two viral variants of distinct biological
characteristics [22]. A comparison of dual-virus inocula-
tion via intrarectal and intravenous routes demonstrates
that a mucosal route of transmission allows greater rela-
tive replication capacity of a less pathogenic virus during
co-infection with a more pathogenic virus, while limiting
t h er a t eo fC D 4
+ T cell decline during the early stages
of infection. However, the variant that replicates more
robustly in CD4
+ T cells eventually dominates. These
results suggest that replication capacity in T cells is a
significant determinant of SIV fitness, but that replica-
tion fitness of the dominant infecting virus may be
reduced after mucosal transmission.
Results
Viral replication fitness in culture is host cell dependent
In vitro competitive replication fitness assays have been
used to determine the fitness of both HIV-1 and SIV
[38-40], but whether these types of assays predict viral
fitness and pathogenicity in vivo has not been examined.
In order to address the predictive value of a cell culture
assay for SIV fitness, we first determined the relative
in vitro competitive replicative fitness of two CCR5-
using phenotypic variants: a minimally pathogenic, par-
ental, virus (SIVmneCl8) and highly pathogenic, late-
stage variant virus (SIVmne027). Both viruses used in
this study have been characterized during in vitro and in
vivo single infection/inoculation studies (Table 1). Three
types of pig-tailed macaque primary cell cultures were
used to examine competitive replication: activated per-
ipheral blood lymphocytes (PBLs), dendritic cell/T cell
(DC/T cell) co-cultures, and monocyte-derived macro-
phage cultures. To monitor the relative amounts of
SIVmneCl8 and SIVmne027 in cell-free culture superna-
tants over time, we developed quantitative real-time
PCR assays that measure the overall amount of viral
RNA by detection of a conserved SIV gag sequence and
the amount of SIVmneCl8 by detection of a unique env
sequence. Using known quantities of SIVmneCl8 and
SIVmne027 viral RNA targets, we determined that the
assay is capable of accurately quantifying SIVmneCl8
even in the presence of 10
5 to 10
6-fold excess of
SIVmne027 (data not shown). Furthermore, when acti-
vated pig-tail PBLs are infected with SIVmneCl8 alone,
we observed a correlation between viral RNA measure-
ments using the SIVmneCl8 env and SIV gag primer/
probe sets (Figure 1a). As expected, SIVmneCl8 env was
not detected in supernatants from SIVmne027 infected
pig-tail (PBLs), even though there was about 3 × 10
9
viral RNA copies/ml of SIVmne027 as determined by
total SIV RNA measurements (Figure 1b). This further
indicated that there was insignificant detection of
SIVmne027 by the SIVmneCl8 env specific real-time
RT-PCR assay. Thus, the data show that SIVmneCl8 can
be specifically detected by the allelic discriminating real-
time PCR assay.
When we analyzed activated PBLs or DC/T cell co-
cultures that were co-infected with equal infectious
doses of SIVmneCl8 and SIVmne027, we observed that
SIVmneCl8 represented a minor fraction (0-30%) of
total viral RNA by the end of each experiment (Figure
2a and 2b). This occurred even if SIVmneCl8 repre-
sented greater than 90% of the virus at early time points
after infection. Similar results were obtained with DC-
T-cell capture-transfer assays (data not shown). By con-
trast, in two of three infections of monocyte-derived
macrophages, SIVmneCl8 represented 100% of total
viral RNA during co-infection (Figure 2c). These data
correlate with the abilities of the two viruses to replicate
under the three culture conditions in single-virus infec-
tions. For example, SIVmne027 replicates efficiently in
activated PBLs and in DC/T cell co-cultures but to low
levels in monocyte-derived macrophages. In contrast,
SIVmneCl8 replicates to lower levels than SIVmne027
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moderate levels in macrophages (Figure 1 and Table 1).
Together, the data demonstrate that SIVmne027 has
greater competitive replication fitness than SIVmneCl8
in activated PBLs and DC/T cell co-cultures, but not in
macrophage cultures.
SIVmne027 exhibits complete dominance over SIVmneCl8
following intravenous inoculation
Since in vitro infection assays are limited to analysis of
viral replication without immune pressures, we co-
inoculated pig-tailed macaques with equal infectious
doses of SIVmneCl8 and SIVmne027 intravenously (IV)
in order to determine relative replicative fitness of these
two viruses within a host. Overall virus replication in
the three macaques peaked at week 1 post-inoculation
between 10
8-10
9 viral RNA copies/mL in plasma and
stabilized around ~10
7 copies/mL (Figure 3a). Peak
values and viral set-point levels in the co-infected ani-
mals are comparable to those seen during single-virus
IV infections of pig-tailed macaques with SIVmne027
and about 30-1000-fold greater than infection with
SIVmneCl8 [22,41]. SIVmneCl8 was undetectable at all
times tested post-infection, indicating that it was unable
to persist at a measurable level during IV co-infection
with SIVmne027. The identification of a recombinant
env sequence in animal 29046 provided confirmation of
SIVmneCl8 infection in these animals (Table 2). These
results show that SIVmne027 is dominant over SIVm-
neCl8 during IV co-infection s .F u r t h e r m o r e ,i nc o n t e x t
of earlier studies with these viruses [22], the data also
suggest that variants that emerge with increased ability
to replicate in CD4
+ T cells and which have increased
pathogenicity are indeed more fit than viruses from
which they evolved in the host.
SIVmneCl8 demonstrates higher relative replication levels
after mucosal inoculation
We next examined what effect a mucosal route of infec-
tion would have on relative viral replication in the host.
Pig-tailed macaques were co-infected intrarectally (IR)
with equal doses of the same SIVmneCl8 and
SIVmne027 stocks used to inoculate animals IV. We
again found overall viral peak values in plasma ranged
between 10
8-10
9 copies/mL (Figure 3b). Interestingly,
post-acute plasma viral loads in IR-infected macaques
varied considerably between individual macaques in
comparison to those in IV-infected animals. Moreover,
SIVmneCl8 was detectable throughout the acute stage
of IR infection and peaked at 8 weeks post-infection.
SIVmneCl8 plasma viral loads increased from undetect-
able to between 1 × 10
5 to 2 × 10
6 viral RNA copies/ml
and represented between 10 and 50% of the virus popu-
lation in plasma (Figure 3b and 4b). However, it even-
tually gave way to SIVmne027, which became
completely dominant with time. Macaque 28490 had the
highest levels of SIVmneCl8, which constituted as much
as 50% of the total virus population at 8 weeks post-
infection, and the lowest overall plasma viral load. The
CD4
+ T cell population in animal 28490 was also well
preserved compared to the other animals (Figure 4c).
Mucosal transmission decreases viral load and rate of
CD4
+ T cell decline
To determine whether the route of transmission affected
overall viral load, CD4
+ T cell decline, and competitive
replication fitness of SIVmneCl8 and SIVmne027, we
compared the results from the IR and IV infections.
Although there was no significant difference in the aver-
age peak plasma viral RNA measurements, we found
peak viral replication significantly delayed (p = 0.0007)
after IR inoculation. The viral set-point averages at
weeks 20 and 24 were also reduced in IR-infected maca-
ques as compared with IV-infected macaques but were
marginally significant (p = 0.0544 and 0.0509, respec-
tively) (Figure 4a). Secondly, a comparison of the level
of SIVmneCl8 in plasma between IV and IR infected
macaques revealed a significantly greater level of SIVm-
n e C l 8a tw e e k2 ,4a n d8( p = 0.049, 0.006 and 0.005,
respectively) in IR-infected macaques, despite the pre-
sence of the more pathogenic variant, SIVmne027 (Fig-
ure 4b). This was verified by single-proviral cloning and
sequencing of env from PBMC isolated at 8 weeks post-
inoculation (Table 2).
An analysis of absolute values of CD4
+ T cells showed
a greater decrease in CD4
+ T cell levels in IV-infected
Table 1 Summary of the phenotypes of the SIV variants
Virus
Type
Name In vivo pathogenesis In vitro Replication Capacity
Relative Viral
Load
#
CD4
+ T cell
decline
Infectivity Co-stimulated
Lymphoblasts
Macrophages Dendritic
Cells
Resting CD4
+
T Cells
DC-T Cell
Co-cultures
Early SIVmneCl8 1/1 Slow Low Low Moderate ND* ND Low
Late SIVmne027 30/4000 Rapid High High Low ND Low High
#Differences in plasma viral loads during the acute and chronic stages (acute/set-point) following intravenous inoculation are indicated relative to SIVmneCl8.
*ND, not detected.
References describing the variant viruses: [21,22,27,34,41,62-67].
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0.0013; week 8-24: p = 0.0006) (Figure 4c). These dif-
ferences were also reflected in the population of cen-
tral memory CD4
+ T cells (Figure 5). Thus, although
t h em o r ep a t h o g e n i ca n dr a p i dly-replicating variant,
SIVmne027, always dominated the co-infections,
mucosal transmission enabled the slower-replicating
SIVmneCl8 to replicate to relatively higher levels dur-
ing the primary stage of infection. Interestingly, this
was associated with lower viral loads and slower initial
Figure 1 Quantitative real-time RT-PCR to measure relative levels of SIVmneCl8 and SIVmne027. The real-time RT-PCR assay was
developed to detect two regions of the viral genome, a conserved gag sequence and an env V1 sequence specific to SIVmneCl8. The relative
amount of SIVmneCl8 was determined from the amount of viral RNA detected by the SIVmneCl8 env V1 specific primer/probe set compared to
the total amount of viral RNA detected by the primer/probe set recognizing the conserved gag sequence. Single-virus infections of activated
pig-tail PBL with SIVmneCl8 (a) or SIVmne027 (b) shows that only SIVmneCl8 is recognized by the env V1 primer/probe, even when the overall
viral RNA level is greater than 1 × 10
9 viral RNA copies/ml of SIVmne027.
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+ T cell decline, suggesting the induction of pro-
tective immune responses by SIVmneCl8. Taken
together, the data indicate that there may be greater
control of SIV after IR infection compared to IV
infection.
Discussion
We examined the relative replicative fitness of phenoty-
pic SIV variants using both in vitro and in vivo co-
infections in order to examine the impact of competi-
tion and target cell availability on relative viral replica-
tion and CD4
+ T cell decline during the early stages of
infection. Our data demonstrate that a rapidly-replicat-
ing, highly pathogenic variant (SIVmne027) that evolved
in vivo is indeed more fit than the slower-replicating
parental virus (SIVmneCl8), regardless of whether co-
inoculation was IV or IR. Furthermore, they confirm
that in vitro competitive replication fitness experiments
may predict replication fitness and pathogenicity in vivo
[38-40]. The data support a model in which the predo-
minant genotype established within a host is defined by
how well a virus has adapted to replicating in CD4
+ T
cells. They also demonstrate that these viruses are likely
to predominate in subsequent transmissions. This model
is consistent with previous in situ studies, which show
that the primary target cells during transmission and
acute HIV-1 and SIV infection are primarily CD4
+ T
cells in lymphoid tissues [42-45].
Figure 2 Dual-virus competition assays in primary pig-tailed macaque cells. Activated PBLs (a), DC/T cell co-cultures (b), and macrophages
(c) were infected with equal doses of SIVmneCl8 and SIVmne027. Total virus was determined by measuring consensus sequence gag RNA
transcripts (–). SIVmneCl8 viral RNA levels were measures and are reported as percentages of total viral RNA (····). Three representative
experiments (black circle/open circle, black triangle/open triangle, and black square/open square) are shown for each graph and viral RNA values
represent the average reading for each time point. Each infection used cells from a different macaque blood donor.
Figure 3 Plasma viral loads from in vivo co-infections. Macaques were infected with equal doses of SIVmneCl8 and SIVmne027 using either
an intravenous route of inoculation (a), animals 29046 (gray circle/open circle), 29047 (gray triangle/open triangle) and 29048 (gray square/open
square) or an intrarectal route of inoculation (b), animals 28488 (black circle/open circle), 28489 (black triangle/open triangle) and 28490 (black
square/open square). Total virus in plasma was determined by measuring consensus sequence gag RNA transcripts (–) by quantitative real-time
PCR. SIVmneCl8 specific viral RNA levels were also measured by quantitative real-time PCR and are reported as percentages of total viral RNA (····).
Viral RNA values represent the average reading for each time point.
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iant, the slower replicating virus, SIVmneCl8, was able
to expand exponentially during the acute stage after IR
co-inoculation. It represented as much as 50% of the
total virus population before giving way to SIVmne027.
This was unexpected, given the nearly complete domi-
nance of SIVmne027 that was observed after IV inocula-
tion, the low competitive replication fitness of
SIVmneCl8 in T cell and DC/T cell cocultures, and our
previous observations that in single-virus infections,
SIVmneCl8 demonstrates both lower initial spike and
set-point plasma viral RNA copies/ml than SIVmne027
in pig-tailed macaques [22,41]. However, the peak levels
achieved by SIVmneCl8 are within range of what has
been observed when it is inoculated alone. One potential
explanation is that the viruses target different cell types
after IR inoculation. For example, the dominant virus,
SIVmne027, may spread in abundant memory CD4
+
T cells. In contrast, the virus with greater relative repli-
cation fitness in macrophages, SIVmneCl8, may be
mainly limited to replication in rectal macrophages,
which are known to be susceptible target cells [14,46].
While challenging, it would be of interest to examine
the infection profile of a dual-virus inoculation and the
cell types harboring virus in the rectum and gut-
associated lymphoid tissue during acute infection.
Alternatively, increased levels of the slower replicating
virus, SIVmneCl8, could be due to immunosuppression
induced by the dominant T-cell tropic variant,
SIVmne027. However, this seems unlikely since higher
levels of SIVmneCl8 were associated with greater preser-
vation of the CD4
+ T cell populations. Potentially, this
association may indicate that SIVmneCl8 only replicates
efficiently in a particular subpopulation of CD4
+ T-cells
that are available after IR inoculation but are depleted
in the IV infected animals.
Some earlier studies have shown that multiple HIV-1
variants can be transmitted in both men and women,
followed by purifying selection [47,48]. On the other
hand, more recent studies indicate that only single HIV-
1 variants appear to be transmitted to new hosts from
the index case [35,36,43]. Furthermore, a low dose SIV
mucosal infection experiment with the SIV isolates SIV-
mac251 and SIVsmE660 also suggested single virus
transmission was frequent [49]. However, a new study
s h o w st h a tm u l t i v a r i a n tt r a nsmission may occur more
frequently in men having sex with men than during het-
erosexual transmission [50]. A second study demon-
strates that multiple variants are commonly transmitted
in low dose vaginal challenge of rhesus macaques with
SIV [51]. The reasons for these contrasting results
remain unclear. One explanation for the differences may
Table 2 Env variants identified by single-genome cloning
Source of DNA Env su sequences
a IR-infected Animals IV-infected Animals
28488 28489 28490 29046 29047 29048
PBMC SIVmneCl8 227000
SIVmne027 14 23 17 14 12 14
Recombinant 000100
Total 16 25 24 15 12 14
aEnv su fragments were cloned from PBMCs harvested eight weeks post infection by nested PCR amplification.
Figure 4 Comparison of IV vs IR viral loads and CD4
+ T cell counts from SIVmneCl8/SIVmne027 co-inoculated macaques. Total plasma
viral RNA transcripts (a), SIVmneCl8 env transcripts (b), and CD4
+ T cell levels (c) from intravenously infected macaques (gray circles, triangles,
and squares) and intrarectally infected macaques (black circles, triangles, and squares) are shown. Viral RNA measurements were determined as
in Fig. 3. Values represent average readings for each time point ± the standard error. Levels of significance are denoted as follows: (**) p < 0.05,
(*) p = 0.05. In panel (a) the p-value at peak plasma viral load is 0.0007. The p-value for differences in viral set-point at 20 and 24 weeks post-
inoculation are 0.0544 and 0.0509, respectively. For panel (b) p-values at 2, 4, and 8 weeks post-inoculation are 0.049, 0.006, and 0.005,
respectively. For panel (c) the p-value for period 0-8 weeks post-inoculation is 0.0013, and the p-value for period 8-24 weeks post-inoculation is
0.0006.
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lessen only when transmission occurs with co-existing
genital infections and inflammation [52]. Regardless,
none of the studies distinguish between limited trans-
mission of variants across the mucosal surface and com-
petitive selection of variants during dissemination and
establishment of infection as the cause for limited viral
diversity.
The animals in this study did not have signs of anal
inflammation. Also, they were not subjected to repeated
low dose exposures to the SIV variants. Thus, we were
not able to address the question of whether one virus is
preferentially transmitted over the other. For the experi-
ments, we used a minimal dose expected to allow 100%
infection by both variants in order to address which var-
iant was likely to establish a more robust persistent
infection if both are given the opportunity to infect the
animals. Our data agree with the potential for rapid pur-
ifying selection after transmission based on competitive
replication fitness if more than one virus is transmitted
[47,48]. The data also raise the possibility that one var-
iant may be highly dominant even if multiple variants
get transmitted. In this regard, caution should be taken
in considering a vaccine design that only targets what
appears to be a commonly transmitted single genotype
of HIV-1. Other variants may simply be hidden because
of the high replication fitness of the predominant virus
or because they are controlled by the host immune
response [53].
Our data suggest that the route of infection may have
a significant effect on the level of viral replication in the
host. Statistically significant lower plasma viral loads
were observed following IR compared to IV inoculation.
Thus, host-specific selective pressures exerted on the
v i r a lp o p u l a t i o n sm a yp l a ya ni m p o r t a n tr o l ei nv a r i a n t
selection in addition to direct viral competition for
resources. These results suggest that a mucosal route of
infection exerts a modest selective pressure for viral var-
iants with lower replicative fitness and pathogenicity
compared to IV infection. Clearly, a shortcoming of our
study is the limited number of animals used per group.
Although the data are statistically significant, further
experiments will be required to verify the results
because of potential variability [54]. However, it is
i m p o r t a n tt on o t et h a tw eh a v ef o u n di np a s te x p e r i -
ments that significant differences are observable with
limited numbers of pig-tailed macaques infected with
SIVmne variant clones [22,41]. Moreover, our data are
in agreement with previous studies with uncloned SIV-
mac251, which also showed decreased viral fitness,
lower viral loads, and pathogenicity after intrarectal
inoculation or passage by intravaginal inoculation of
Figure 5 Comparison of central memory CD4
+ T cells in intrarectally-infected and intravenously-infected pig-tailed macaques.
Individual data points from intrarectally-infected animals (thin dotted lines with open symbols) with the predicted mean value (thick dotted line;
Group 1) were compared with data from intravenously-infected animals (thin solid lines with closed symbols) with the predicted mean value
(thick solid line; Group 2). Significant differences were found at all time points from week 1 through week 20. P-values for all time points (0, 1, 2,
4, 6, 8, 12, 16, 20, 24) are given here: 0.0528, <0.0001, <0.0001, <0.0001, <0.0001, <0.0001, 0.0003, 0.0009, 0.0585 and 0.9761 respectively.
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pathogenicity of SIV that occur with serial intravenous
passage [22,25], vaginal and rectal routes of infection
may not lead to increased virulence and rate of progres-
sion to AIDS. It is unknown if these findings are parti-
cular to the viruses used for the studies. The use of
molecular clones will allow us to compare the results of
the current experiments with those using a different
combination of cloned variant viruses.
Previous studies of recombination in SIVmac-infected
rhesus macaques indicated rapid selection for recombi-
nants with increased replication fitness [57,58]. Recom-
bination in the present study was rarely observed. One
reason for the difference in results may be because the
sequences analyzed in our study were primarily
restricted to the env gene. However, we have also exam-
ined a limited number of complete proviral genomes
(4 total) and env-nef-LTR sequences (approximately 40)
PCR amplified from the IR-inoculated animals but have
not found evidence for recombination (C. Gingaras and
J.T. Kimata, unpublished observations). An alternative
explanation may be a methodological difference. Both
earlier studies on SIV recombination co-inoculated ani-
mals with two mutants with deletions in either vpr/vpx
or nef. In that scenario, recombination may readily
occur to form variants with wild type genomes that are
more fit for persistent replication and are therefore
dominant. In the current experiments, we co-inoculated
two variants with different replicative and pathogenic
phenotypes but no deletion mutations. Recombinants
may not have had a clear advantage for persistence
compared to the dominant SIVmne027 variant.
Whether the level of replication of the slower replicating
SIVmneCl8 contributes to the decrease in plasma viral
load that occurs after IR inoculation is unknown and will
require further investigation. Although it is possible that
SIVmneCl8 induces protective immune responses against
SIVmne027, we previously demonstrated that a prime/
boost vaccine based on SIVmneCl8 fails to protect or
lower viral load in macaques challenged by another highly
related variant SIVmne [41], suggesting the SIVmneCl8
infection may not prime an effective immune response
against SIVmne027 either. However, we cannot rule out
t h a tam o r er o b u s ti m m u n er esponse is induced during
intrarectal infection preventing gains replic.
It will be of interest to determine whether continued
mucosal passage of variants from SIVmneCl8/
SIVmne027 infected macaques leads to additional reduc-
tions in viral fitness and lengthening of the time to dis-
ease, and to determine what immune responses
contribute to the lower replication level of SIV after
intrarectal inoculation. The results could provide impor-
tant insights into host immune mechanisms that can
contain infection and select for less pathogenic variants.
As HIV-1 is primarily sexually transmitted, the reduc-
tions in viral load observed following mucosal infection
and passage in the macaque may also provide an explain
for why the overall rate of HIV disease progression in
the general human population has remained relatively
constant, or even decreased, despite the adaptations
affecting pathogenicity that occur in the virus during
the course of infection of an individual [59-61].
Conclusions
Previous studies demonstrated that HIV/SIV variants
that evolve during an infection have increased competi-
tive replication fitness compared to the infecting virus.
We further those studies by showing in the macaque
host that an SIV variant with increased pathogenicity,
dominates infection when co-inoculated either IR or IV
into a host along with the parent virus from which it
evolved. We conclude that replication fitness evolves
with pathogenicity and that variants that replicate most
efficiently in CD4
+ T cells are likely to dominate after
subsequent infections. However, IR infection supported
relatively higher replication of the less competitively fit
virus despite replication of the more pathogenic variant,
suggesting that the rectal environment provides greater
target cell availability for replication of phenotypically
diverse variants. Finally, our data agree with earlier stu-
dies suggesting that mucosal infections, unlike IV infec-
tions, may curtail increases in viral replication fitness
and rate of CD4
+ T cell decline, thereby preventing an
increase in the rate of disease progression with passage
of the virus to new hosts.
Materials and methods
Cell culture and Viruses
Primary pig-tailed macaque cells were cultured in
RPMI1640 supplemented with 10% heat-inactivated fetal
bovine serum (HI-FBS), 2 mM L-glutamine, and 100 U/
mL penicillin and 100 μg/mL streptomycin (P/S) (RPMI
complete) with additional cytokines as required. sMAGI
cells were maintained in DMEM, 10% HI-FBS, 2 mM L-
glutamine, P/S (DMEM complete) with 0.20 mg/mL
G418 and 50 U/mL hygromycin B. The cloning of the
variant viruses, SIVmneCl8 and SIVmne027, were
described previously [22,62,63]. Characteristics of each
virus are summarized in Table 1[21,22,27,34,41,62-67].
Infectious SIVmneCl8 and SIVmne027 stocks were pre-
pared by transfection of plasmid DNA containing the
respective provirus into 293T cells, and virus stocks
(infectious units (IU)/ml) were quantified using the
sMAGI assay as described [68].
In vitro viral infections
Peripheral blood mononuclear cells were isolated from
pig-tailed macaque blood using Ficoll-hypaque isolation.
Biesinger et al. Retrovirology 2010, 7:88
http://www.retrovirology.com/content/7/1/88
Page 8 of 12Blood donor animals are different from those used for
the in vivo inoculations described below. Monocytes
were depleted by adherence and the remaining periph-
eral blood lymphocytes (10
5-10
6 cells/well) were seeded
into a 24-well plate coated with anti-CD3 and anti-
CD28 per well for co-stimulation and then used for viral
replication assays as described [34]. Equal infectious
doses of SIVmneCl8 and SIVmne027 (MOI = 0.001 for
each virus) were added to each well in ~200 μlv o l u m e
and incubated for 3 hours. Cells were washed twice with
PBS to remove any unbound virus and resuspended in
RPMI complete + 50 U/mL IL-2 (RPMI/IL-2). Superna-
tant samples were collected and media replaced with
RPMI/IL-2 every 2-3 days. Viral RNA was isolated using
QIAamp Viral RNA minikit (Qiagen). Samples were
analyzed with real-time RT PCR as described below to
quantify total SIV and SIVmneCl8 specific viral RNA.
Dendritic cell (DC)/T-cell co-cultures were prepared
from monocytes and T-cells isolated from the blood of
individual macaques as described [67]. Five days after
isolation, monocyte-derived DCs and T-cells were mixed
and equal doses of both SIVmneCl8 and SIVmne027
(2 × 10
3 IU; MOI = 0.01 relative to T cells) were added
to the co-cultures, incubated for 3 hours, and washed
twice with PBS to remove unbound virus. Co-cultures
were resuspended in RPMI/IL-2. Alternatively, viruses
were first captured by DCs and then transferred to
T-cells (DC-T-cell capture-transfer assay) as described
[67]. Supernatant samples were collected and media
replaced every 2-3 days. Viral RNA was isolated using
QIAamp Viral RNA minikit (Qiagen). Samples were
analyzed with real-time RT PCR as described.
Macrophages were differentiated from monocytes iso-
lated by plastic adherence from pig-tailed macaque
PBMCs as described previously [62,66]. Cultures were
inoculated with equal doses of SIVmneCl8 and
SIVmne027 (MOI 0.01), washed twice with PBS to
removed unbound virus after 4 hours, and cultured in
RPMI complete media. Supernatant samples were col-
lected every 2-3 days and media replaced with fresh
media. Viral RNA was isolated from samples using
QIAamp Viral RNA minikit (Qiagen). Samples were
analyzed with real-time RT PCR as described.
In vivo inoculations of macaques
Six pig-tailed macaques (three per group) were infected
either intravenously or by atraumatic intrarectal inocula-
tion with 1 × 10
4 IU each of SIVmneCl8 and
SIVmne027 using previously described methods
[22,69,70]. This dose was experimentally determined to
be the minimum required to inoculate 100% of pig-
tailed macaques with an uncloned infectious stock of
SIVmne by the rectal route [71]. Animal care and usage
were performed in accordance with protocols approved
by the Institutional Animal Care and Use Committee of
the Southwest Foundation for Biomedical Research and
were conducted in accordance with Animal Welfare Act
guidelines.
PCR cloning
Env fragments were cloned from DNA of PBMCs har-
vested eight weeks post infection by nested PCR using
previously described methods [72]. Individual clones
were amplified from PBMC DNA after limiting dilution
of each specimen determined the minimal amount of
DNA required to amplify a proviral env sequence. Env
fragments were cloned into pCR2.1-TOPO vector using
the TOPO TA Cloning Kit (Invitrogen) according to the
manufacturer’s protocol. Sequences were analyzed for
identity to the parental viruses, SIVmneCl8 or
SIVmne027, or for possible recombination.
Real-time RT PCR Assay
RNA standards for detecting gag and SIVmneCl8 env V1
sequences were prepared from plasmid stocks pKS
+-
BamHI-KpaI (pKS
+ plasmid containing BamHI-KpaI
fragment of SIVmneCl8 gag) and pSK
+-Cl8.Env (pSK
+
plasmid containing the fragment 219-570 of SIVmneCl8
env) by in vitro transcription. RNA sample and standard
dilutions were prepared in DEPC-H2O+5 0U / m L
RNase Inhibitor (Invitrogen) and 0.1 μg/μL yeast tRNA
(Sigma). Plates were prepared with 40 μLo fa nR TP C R
master mix (25 μL 2× RT PCR master mix, 1.25 μL 40×
RNase inhibitor mix, 12.92 μL DEPC-H2O and 0.83 μL
60× GAG primer/probe mix [forward primer:
TGTCAGGGAAGAAAGCAGATGAATT; reverse pri-
mer: TGCCCATACTACATGCTTCAACAT; dye, probe
sequence and quencher: FAM-CCGGGTCGTAGCC-
TAA-MGB NFQ] for gag detection and for specific
d e t e c t i o no ft h eS I V m n e C l 8E n v1 2 . 5μL DEPC-H2O
plus [0.25 μL 200× forward primer CAACAGCACCAA-
CAGCAATACC, 0.25 μL 200× reverse primer ACAAG-
GACTATTCTCATTGACCACTTT and 1.25 μL4 0 ×
Env Probe VIC-ACAAAAGCAGAGGCAAT-MGB
NFQ] (Applied Biosystems). 10 μL of standard or sam-
ple was then added and plates were analyzed with a
standard cycling procedure on a 7500 Real Time PCR
System with SDS 1.0 software (Applied Biosystems).
Non-templated and no RT controls were prepared as
above, but substituting DEPC-H2O for template RNA or
a 2× DNA Master Mix (Applied Biosystems) for the 2×
RT PCR Master Mix, respectively. Validation assays
were performed to demonstrate accuracy and specificity
of the primer/probe sets.
Flow Cytometry Analysis
CD4
+ T cell counts were determined by multiplying the
total lymphocytes counts by the fractional amount of
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+CD3
+ T cells. Central memory CD4
+ T cells were
determined by multiplying the number of CD4
+ T cells
by the fractional amount of CD95
+CD28
+ cells in the
CD4
+ T cell gate. Percentages of CD4
+ Tc e l l sw e r e
determined by 5-color flow cytometry using antibodies
from Becton Dickinson: anti-CD3-Alexa 700 (SP34-2),
anti-CD4-APC, anti-CD95-FITC (DX2), anti-CD8-
PerCP, and anti-CD28-APC (28.2).
Statistical Methods
For comparative analysis of total SIV virion RNA and
that of SIVmneCl8 between IV and IR infected maca-
ques a mixed model was used with fixed effects using
SP (POW) for variance-covariance structure. This
approach was also used for comparing memory CD4
+
T cells. To meet the normality assumption for the
model, natural logarithm transferred variable
(Ln_CMCD4) were used in the analysis. The analysis of
total CD4
+ T cell counts used one-way ANOVA for
repeated measures.
Acknowledgements
The authors would like to dedicate this manuscript to the memory of
Jonathan Allan. We thank Claudia Kozinetz and Xiaoying Yu of the Baylor-UT
Houston CFAR design and analysis core for help with statistical analyses of
the data and the veterinary staff at the SNPRC for assistance with the animal
studies. Support was provided by NIH grant R01 AI047725, and in part by
the Baylor-UT Houston CFAR (P30 AI036211), the Southwest National Primate
Research Center (P51 RR13986), the Washington National Primate Research
Center (P51 RR000166), and NIH training grant in Molecular Virology (T32
AI07471).
Author details
1Department of Molecular Virology and Microbiology, Baylor College of
Medicine, Houston, TX 77030, USA.
2Department of Virology and
Immunology, Southwest Foundation for Biomedical Research, San Antonio,
TX 77227, USA.
3Southwest National Primate Research Center, Southwest
Foundation for Biomedical Research, San Antonio, TX 77227, USA.
Authors’ contributions
JSA, JTK, and TB designed the experiments. TB performed most of the
experiments, and analyzed the data. JSA, RW, and BKW assisted with the
macaque infections and the flow cytometry analyses. MTY performed the
PCR cloning. TB and JTK wrote the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 12 July 2010 Accepted: 13 October 2010
Published: 13 October 2010
References
1. Ball CL, Gilchrist MA, Coombs D: Modeling within-host evolution of HIV:
mutation, competition and strain replacement. Bull Math Biol 2007,
69:2361-2385.
2. Tsui R, Herring BL, Barbour JD, Grant RM, Bacchetti P, Kral A, Edlin BR,
Delwart EL: Human immunodeficiency virus type 1 superinfection was
not detected following 215 years of injection drug user exposure. J Virol
2004, 78:94-103.
3. Althaus CL, De Boer RJ: Dynamics of immune escape during HIV/SIV
infection. PLoS Comput Biol 2008, 4:e1000103.
4. Arien KK, Gali Y, El-Abdellati A, Heyndrickx L, Janssens W, Vanham G:
Replicative fitness of CCR5-using and CXCR4-using human
immunodeficiency virus type 1 biological clones. Virology 2006, 347:65-74.
5. Clapham PR, McKnight A: HIV-1 receptors and cell tropism. Br Med Bull
2001, 58:43-59.
6. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A,
Block BL, Brumme ZL, Brumme CJ, Baker B, et al: HLA-B57/B*5801 human
immunodeficiency virus type 1 elite controllers select for rare gag
variants associated with reduced viral replication capacity and strong
cytotoxic T-lymphocyte [corrected] recognition. J Virol 2009, 83:2743-2755.
7. Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, Tebit DM,
Zhao H, Avila S, Lobritz MA, et al: Variable fitness impact of HIV-1 escape
mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 2009,
5:e1000365.
8. Allen TM, Altfeld M, Yu XG, O’Sullivan KM, Lichterfeld M, Le Gall S, John M,
Mothe BR, Lee PK, Kalife ET, et al: Selection, transmission, and reversion of
an antigen-processing cytotoxic T-lymphocyte escape mutation in
human immunodeficiency virus type 1 infection. J Virol 2004,
78:7069-7078.
9. Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, Carlson JM,
Derdeyn CA, Tang J, Kaslow RA, Bansal A, et al: Transmission of HIV-1 Gag
immune escape mutations is associated with reduced viral load in
linked recipients. J Exp Med 2008, 205:1009-1017.
10. Gao Y, Paxinos E, Galovich J, Troyer R, Baird H, Abreha M, Kityo C,
Mugyenyi P, Petropoulos C, Arts EJ: Characterization of a subtype D
human immunodeficiency virus type 1 isolate that was obtained from
an untreated individual and that is highly resistant to nonnucleoside
reverse transcriptase inhibitors. J Virol 2004, 78:5390-5401.
11. Harrigan PR, Bloor S, Larder BA: Relative replicative fitness of zidovudine-
resistant human immunodeficiency virus type 1 isolates in vitro. J Virol
1998, 72:3773-3778.
12. Weber J, Rangel HR, Chakraborty B, Tadele M, Martinez MA, Martinez-
Picado J, Marotta ML, Mirza M, Ruiz L, Clotet B, et al: A novel TaqMan real-
time PCR assay to estimate ex vivo human immunodeficiency virus type
1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J
Gen Virol 2003, 84:2217-2228.
13. Nielsen C, Pedersen C, Lundgren JD, Gerstoft J: Biological properties of HIV
isolates in primary HIV infection: consequences for the subsequent
course of infection. AIDS 1993, 7:1035-1040.
14. Phillips AN, McLean AR, Loveday C, Tyrer M, Bofill M, Devereux H, Madge S,
Dykoff A, Drinkwater A, Burke A, et al: In vivo HIV-1 replicative capacity in
early and advanced infection. AIDS 1999, 13:67-73.
15. Tuttle DL, Anders CB, Aquino-De Jesus MJ, Poole PP, Lamers SL, Briggs DR,
Pomeroy SM, Alexander L, Peden KW, Andiman WA, et al: Increased
replication of non-syncytium-inducing HIV type 1 isolates in monocyte-
derived macrophages is linked to advanced disease in infected children.
AIDS Res Hum Retroviruses 2002, 18:353-362.
16. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD: Genotypic and
phenotypic characterization of HIV-1 patients with primary infection.
Science 1993, 261:1179-1181.
17. Kimata JT: HIV-1 fitness and disease progression: insights from the SIV-
macaque model. Curr HIV Res 2006, 4:65-77.
18. Chackerian B, Rudensey LM, Overbaugh J: Specific N-linked and O-linked
glycosylation modifications in the envelope V1 domain of simian
immunodeficiency virus variants that evolve in the host alter
recognition by neutralizing antibodies. J Virol 1997, 71:7719-7727.
19. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, Cullen C, Evans DT,
Desrosiers RC, Mothe BR, Sidney J, et al: Reversion of CTL escape-variant
immunodeficiency viruses in vivo. Nat Med 2004, 10:275-281.
20. Loh L, Reece JC, Fernandez CS, Alcantara S, Center R, Howard J, Purcell DF,
Balamurali M, Petravic J, Davenport MP, Kent SJ: Complexity of the
inoculum determines the rate of reversion of SIV Gag CD8 T cell mutant
virus and outcome of infection. PLoS Pathog 2009, 5:e1000378.
21. Rudensey LM, Kimata JT, Long EM, Chackerian B, Overbaugh J: Changes in
the extracellular envelope glycoprotein of variants that evolve during
the course of simian immunodeficiency virus SIVMne infection affect
neutralizing antibody recognition, syncytium formation, and
macrophage tropism but not replication, cytopathicity, or CCR-5
coreceptor recognition. J Virol 1998, 72:209-217.
Biesinger et al. Retrovirology 2010, 7:88
http://www.retrovirology.com/content/7/1/88
Page 10 of 1222. Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J: Emerging
cytopathic and antigenic simian immunodeficiency virus variants
influence AIDS progression. Nat Med 1999, 5:535-541.
23. Alexander L, Illyinskii PO, Lang SM, Means RE, Lifson J, Mansfield K,
Desrosiers RC: Determinants of increased replicative capacity of serially
passaged simian immunodeficiency virus with nef deleted in rhesus
monkeys. J Virol 2003, 77:6823-6835.
24. Du Z, Lang SM, Sasseville VG, Lackner AA, Ilyinskii PO, Daniel MD, Jung JU,
Desrosiers RC: Identification of a nef allele that causes lymphocyte
activation and acute disease in macaque monkeys. Cell 1995, 82:665-674.
25. Edmonson P, Murphey-Corb M, Martin LN, Delahunty C, Heeney J,
Kornfeld H, Donahue PR, Learn GH, Hood L, Mullins JI: Evolution of a
simian immunodeficiency virus pathogen. J Virol 1998, 72:405-414.
26. Fultz PN: Replication of an acutely lethal simian immunodeficiency virus
activates and induces proliferation of lymphocytes. J Virol 1991,
65:4902-4909.
27. Patel PG, Yu Kimata MT, Biggins JE, Wilson JM, Kimata JT: Highly
pathogenic simian immunodeficiency virus mne variants that emerge
during the course of infection evolve enhanced infectivity and the
ability to downregulate CD4 but not class I major histocompatibility
complex antigens. J Virol 2002, 76:6425-6434.
28. Heidecker G, Munoz H, Lloyd P, Hodge D, Ruscetti FW, Morton WR, Hu S,
Benveniste RE: Macaques infected with cloned simian immunodeficiency
virus show recurring nef gene alterations. Virology 1998, 249:260-274.
29. Iafrate AJ, Carl S, Bronson S, Stahl-Hennig C, Swigut T, Skowronski J,
Kirchhoff F: Disrupting surfaces of nef required for downregulation of
CD4 and for enhancement of virion infectivity attenuates simian
immunodeficiency virus replication in vivo. J Virol 2000, 74:9836-9844.
30. Sugimoto C, Tadakuma K, Otani I, Moritoyo T, Akari H, Ono F, Yoshikawa Y,
Sata T, Izumo S, Mori K: nef gene is required for robust productive
infection by simian immunodeficiency virus of T-cell-rich paracortex in
lymph nodes. J Virol 2003, 77:4169-4180.
31. Schindler M, Munch J, Brenner M, Stahl-Hennig C, Skowronski J, Kirchhoff F:
Comprehensive analysis of nef functions selected in simian
immunodeficiency virus-infected macaques. J Virol 2004, 78:10588-10597.
32. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, O’Connor S, Marx PA,
Meythaler M, Goldstein S, Buckler-White A, et al: TRIM5 suppresses cross-
species transmission of a primate immunodeficiency virus and selects
for emergence of resistant variants in the new species. PLoS Biol 8.
33. Jesus da Costa L, Lopes Dos Santos A, Mandic R, Shaw K, Santana de
Aguiar R, Tanuri A, Luciw PA, Peterlin BM: Interactions between SIVNef,
SIVGagPol and Alix correlate with viral replication and progression to
AIDS in rhesus macaques. Virology 2009, 394:47-56.
34. Biesinger T, Yu Kimata MT, Kimata JT: Changes in simian
immunodeficiency virus reverse transcriptase alleles that appear during
infection of macaques enhance infectivity and replication in CD4+ T
cells. Virology 2008, 370:184-193.
35. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M,
Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, et al: Envelope-
constrained neutralization-sensitive HIV-1 after heterosexual
transmission. Science 2004, 303:2019-2022.
36. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG,
Sun C, Grayson T, Wang S, Li H, et al: Identification and characterization of
transmitted and early founder virus envelopes in primary HIV-1
infection. Proc Natl Acad Sci USA 2008, 105:7552-7557.
37. Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, Ho DD:
Genetic characterization of human immunodeficiency virus type 1 in
blood and genital secretions: evidence for viral compartmentalization
and selection during sexual transmission. J Virol 1996, 70:3098-3107.
38. Quinones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, Vanham G,
van Der Groen G, Colebunders RL, Arts EJ: A dual infection/competition
assay shows a correlation between ex vivo human immunodeficiency
virus type 1 fitness and disease progression. J Virol 2000, 74:9222-9233.
39. Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, Krizan RW,
Toossi Z, Colebunders RL, Jensen MA, Mullins JI, et al: Changes in human
immunodeficiency virus type 1 fitness and genetic diversity during
disease progression. J Virol 2005, 79:9006-9018.
40. Voronin Y, Overbaugh J, Emerman M: Simian immunodeficiency virus
variants that differ in pathogenicity differ in fitness under rapid cell
turnover conditions. J Virol 2005, 79:15091-15098.
41. Polacino P, Cleveland B, Zhu Y, Kimata JT, Overbaugh J, Anderson D, Hu SL:
Immunogenicity and protective efficacy of Gag/Pol/Env vaccines derived
from temporal isolates of SIVmne against cognate virus challenge. JM e d
Primatol 2007, 36:254-265.
42. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M: Massive
infection and loss of memory CD4+ T cells in multiple tissues during
acute SIV infection. Nature 2005, 434:1093-1097.
43. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H,
Decker JM, Wang S, Baalwa J, Kraus MH, et al: Genetic identity, biological
phenotype, and evolutionary pathways of transmitted/founder viruses in
acute and early HIV-1 infection. J Exp Med 2009, 206:1273-1289.
44. Schacker T, Little S, Connick E, Gebhard K, Zhang ZQ, Krieger J, Pryor J,
Havlir D, Wong JK, Schooley RT, et al: Productive infection of T cells in
lymphoid tissues during primary and early human immunodeficiency
virus infection. J Infect Dis 2001, 183:555-562.
45. Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA,
Reinhart TA, Rogan M, Cavert W, Miller CJ, et al: Sexual transmission and
propagation of SIV and HIV in resting and activated CD4+ T cells. Science
1999, 286:1353-1357.
46. Mestecky J, Moldoveanu Z, Smith PD, Hel Z, Alexander RC: Mucosal
immunology of the genital and gastrointestinal tracts and HIV-1
infection. J Reprod Immunol 2009, 83:196-200.
47. Learn GH, Muthui D, Brodie SJ, Zhu T, Diem K, Mullins JI, Corey L: Virus
population homogenization following acute human immunodeficiency
virus type 1 infection. J Virol 2002, 76:11953-11959.
48. Long EM, Martin HL Jr, Kreiss JK, Rainwater SM, Lavreys L, Jackson DJ,
Rakwar J, Mandaliya K, Overbaugh J: Gender differences in HIV-1 diversity
at time of infection. Nat Med 2000, 6:71-75.
49. Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, Sun C, Chen Y,
Yeh WW, Letvin NL, et al: Low-dose rectal inoculation of rhesus
macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal
infection by HIV-1. J Exp Med 2009, 206:1117-1134.
50. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, Salazar-Gonzalez JF,
Salazar MG, Learn GH, Morgan CJ, et al: High Multiplicity Infection by HIV-
1 in Men Who Have Sex with Men. PLoS Pathog 6:e1000890.
51. Stone M, Keele BF, Ma ZM, Bailes E, Dutra J, Hahn BH, Shaw GM, Miller CJ:
A limited number of simian immunodeficiency virus (SIV) env variants
are transmitted to rhesus macaques vaginally inoculated with
SIVmac251. J Virol 84:7083-7095.
52. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E,
Manigart O, Mulenga J, Keele BF, Shaw GM, et al: Inflammatory genital
infections mitigate a severe genetic bottleneck in heterosexual
transmission of subtype A and C HIV-1. PLoS Pathog 2009, 5:e1000274.
53. Harouse JM, Buckner C, Gettie A, Fuller R, Bohm R, Blanchard J, Cheng-
Mayer C: CD8+ T cell-mediated CXC chemokine receptor 4-simian/
human immunodeficiency virus suppression in dually infected rhesus
macaques. Proc Natl Acad Sci USA 2003, 100:10977-10982.
54. Parker RA, Regan MM, Reimann KA: Variability of viral load in plasma of
rhesus monkeys inoculated with simian immunodeficiency virus or
simian-human immunodeficiency virus: implications for using
nonhuman primate AIDS models to test vaccines and therapeutics. J
Virol 2001, 75:11234-11238.
55. Greenier JL, Miller CJ, Lu D, Dailey PJ, Lu FX, Kunstman KJ, Wolinsky SM,
Marthas ML: Route of simian immunodeficiency virus inoculation
determines the complexity but not the identity of viral variant
populations that infect rhesus macaques. J Virol 2001, 75:3753-3765.
56. Trivedi P, Horejsh D, Hinds SB, Hinds PW II, Wu MS, Salvato MS, Pauza CD:
Intrarectal transmission of simian immunodeficiency virus in rhesus
macaques: selective amplification and host responses to transient or
persistent viremia. J Virol 1996, 70:6876-6883.
57. Kim EY, Busch M, Abel K, Fritts L, Bustamante P, Stanton J, Lu D, Wu S,
Glowczwskie J, Rourke T, et al: Retroviral recombination in vivo: viral
replication patterns and genetic structure of simian immunodeficiency
virus (SIV) populations in rhesus macaques after simultaneous or
sequential intravaginal inoculation with SIVmac239Deltavpx/Deltavpr
and SIVmac239Deltanef. J Virol 2005, 79:4886-4895.
58. Wooley DP, Smith RA, Czajak S, Desrosiers RC: Direct demonstration of
retroviral recombination in a rhesus monkey. J Virol 1997, 71:9650-9653.
59. Arien KK, Troyer RM, Gali Y, Colebunders RL, Arts EJ, Vanham G: Replicative
fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation
over time. AIDS 2005, 19:1555-1564.
Biesinger et al. Retrovirology 2010, 7:88
http://www.retrovirology.com/content/7/1/88
Page 11 of 1260. Gali Y, Berkhout B, Vanham G, Bakker M, Back NK, Arien KK: Survey of the
temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort.
Virology 2007, 364:140-146.
61. Muller V, Ledergerber B, Perrin L, Klimkait T, Furrer H, Telenti A,
Bernasconi E, Vernazza P, Gunthard HF, Bonhoeffer S: Stable virulence
levels in the HIV epidemic of Switzerland over two decades. AIDS 2006,
20:889-894.
62. Kimata JT, Mozaffarian A, Overbaugh J: A lymph node-derived cytopathic
simian immunodeficiency virus Mne variant replicates in nonstimulated
peripheral blood mononuclear cells. J Virol 1998, 72:245-256.
63. Rudensey LM, Kimata JT, Benveniste RE, Overbaugh J: Progression to AIDS
in macaques is associated with changes in the replication, tropism, and
cytopathic properties of the simian immunodeficiency virus variant
population. Virology 1995, 207:528-542.
64. Forte S, Harmon ME, Pineda MJ, Overbaugh J: Early- and intermediate-
stage variants of simian immunodeficiency virus replicate efficiently in
cells lacking CCR5. J Virol 2003, 77:9723-9727.
65. Kimata JT, Overbaugh J: The cytopathicity of a simian immunodeficiency
virus Mne variant is determined by mutations in Gag and Env. J Virol
1997, 71:7629-7639.
66. Kimata JT, Wilson JM, Patel PG: The increased replicative capacity of a
late-stage simian immunodeficiency virus mne variant is evident in
macrophage- or dendritic cell-T-cell cocultures. Virology 2004,
327:307-317.
67. Yu Kimata MT, Cella M, Biggins JE, Rorex C, White R, Hicks S, Wilson JM,
Patel PG, Allan JS, Colonna M, Kimata JT: Capture and transfer of simian
immunodeficiency virus by macaque dendritic cells is enhanced by DC-
SIGN. J Virol 2002, 76:11827-11836.
68. Chackerian B, Haigwood NL, Overbaugh J: Characterization of a CD4-
expressing macaque cell line that can detect virus after a single
replication cycle and can be infected by diverse simian
immunodeficiency virus isolates. Virology 1995, 213:386-394.
69. Kuller L, Thompson J, Watanabe R, Iskandriati D, Alpers CE, Morton WR,
Agy MB: Mucosal antibody expression following rapid SIV(Mne)
dissemination in intrarectally infected Macaca nemestrina. AIDS Res Hum
Retroviruses 1998, 14:1345-1356.
70. Polacino P, Stallard V, Montefiori DC, Brown CR, Richardson BA, Morton WR,
Benveniste RE, Hu SL: Protection of macaques against intrarectal infection
by a combination immunization regimen with recombinant simian
immunodeficiency virus SIVmne gp160 vaccines. J Virol 1999,
73:3134-3146.
71. Kuller L, Benveniste RE, Tsai CC, Clark EA, Polacino P, Watanabe R,
Overbaugh J, Katze MG, Morton WR: Intrarectal inoculation of macaques
by the simian immunodeficiency virus, SIVmne E11S: CD4+ depletion
and AIDS. J Med Primatol 1994, 23:397-409.
72. Overbaugh J, Rudensey LM, Papenhausen MD, Benveniste RE, Morton WR:
Variation in simian immunodeficiency virus env is confined to V1 and
V4 during progression to simian AIDS. J Virol 1991, 65:7025-7031.
doi:10.1186/1742-4690-7-88
Cite this article as: Biesinger et al.: Relative replication capacity of
phenotypic SIV variants during primary infections differs with route of
inoculation. Retrovirology 2010 7:88.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Biesinger et al. Retrovirology 2010, 7:88
http://www.retrovirology.com/content/7/1/88
Page 12 of 12